Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and delivers medicines for life-threatening diseases, with a primary focus on virology, oncology, and inflammation. The company's commercial portfolio includes therapies for HIV, viral hepatitis, cancer, and other conditions. Key products in the HIV space include Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo. In liver disease, Gilead offers Epclusa, Livdelzi, and Vemlidy. Its oncology portfolio features CAR T-cell therapies Tecartus and Yescarta, as well as the antibody-drug conjugate Trodelvy. Other approved medicines include AmBisome for invasive fungal infections and Veklury for COVID-19. The company markets products globally through its own commercial teams, third-party distributors, and corporate partners. Gilead also generates revenue from royalties, intellectual property sales, and collaborations with third-party partners, including Johnson & Johnson for certain HIV products. The company maintains a pipeline of investigational therapies across its three core therapeutic areas.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage gilead.com
Sector Healthcare IR page investors.gilead.com/overview/default.aspx
Tags
hiv, hepatitis, oncology, car t-cell therapy, antibody-drug conjugates, antivirals, inflammation, virology, biopharmaceuticals, life-threatening diseases, Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo, Epclusa, Livdelzi, Vemlidy, Tecartus, Trodelvy, Yescarta, AmBisome, Veklury, Asegua Therapeutics LLC, Janssen Products LP
Press page gilead.com/news

Metrics

Valuation  
Market cap $ 212.279B
Market cap (USD) $ 212.279B
P/E -54.30
PEG —
P/BV 16.28
P/S 6.85
P/OCF 14.66
P/FCF 15.40
Dividend yield 1.9%
Turnover / mcap —
Returns  
ROE 40.5%
ROI 17.9%
ROIC 18.3%
Profit margin 28.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 22.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 201.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 99
Quality score 26.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 29.443B 28.754B 27.116B 27.281B 27.305B 24.689B 22.449B 22.127B 26.107B 30.39B 32.639B 24.89B 11.202B 9.703B 8.385B 7.949B 7.011B 5.336B 4.23B 3.026B 2.028B 1.325B 867.864M 466.79M 233.769M 195.555M
Net profit 8.51B 480M 5.665B 4.592B 6.225B 123M 5.386B 5.455B 4.628B 13.501B 18.108B 12.101B 3.075B 2.592B 2.804B 2.901B 2.636B 2.011B 1.615B -1.19B 813.914M 449.371M -72.003M 72.097M 52.271M -56.776M
Free cash flow 9.456B 10.305B 7.421B 8.344B 10.805B 7.518B 8.319B 7.476B 11.308B 15.921B 19.582B 12.261B 2.971B 2.798B 3.507B 2.772B 2.85B — — — — — — 56.812M -114.461M -53.823M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 122.74 92.37 81.01 85.85 72.61 58.26 64.98 62.55 71.64 71.61 101.19 94.26 75.1 73.45 40.93 36.24 43.28 51.13 46 64.49 — — — — — —
Price performance 12m 0.33 0.14 -0.06 0.18 0.25 -0.1 0.04 -0.13 0 -0.29 0.07 0.26 0.02 0.79 0.13 -0.16 -0.15 0.11 -0.29 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 4.51B 3.85B 3.33B 3.58B 4.89B 4.49B 4.78B 4.66B 4.42B 4.91B
↳ YoY growth -22.9% -14.7% -13.6% +7.7% +36.6% -8.2% +6.3% -2.4% -5.2% +11.2%
↳ 5y CAGR +18.3% +17.1% +9.6% -5.0% -3.5% -0.1% +4.4% +7.0% +4.3% +0.1%
Borrowings, current (USD) 0.00 2.75B 2.75B 2.5B 2.76B 1.52B 2.27B 1.8B 1.82B 2.81B
Borrowings, non-current (USD) 26.3B 30.8B 24.6B 22.1B 28.6B 25.2B 23B 23.2B 24.9B 22.1B
Lease liabilities (USD) — — 500M 725M 715M 590M 578M 671M 611M 605M
Cash and deposits (USD) 8.23B 7.59B 17.9B 11.6B 6B 5.34B 5.41B 6.09B 9.99B 7.56B
Intangible assets (USD) 8.97B 17.1B 15.7B 13.8B 33.1B 33.5B 28.9B 26.5B 19.9B 17B
Right-of-use assets (USD) — — 500M 668M 646M 542M 505M 581M 515M 532M
Net debt (borrowings + leases - cash) (USD) 18.1B 26B 9.88B 13.7B 26.1B 21.9B 20.4B 19.6B 17.3B 18B
Cash flow detail
Operating cash flow (USD) 16.7B 11.9B 8.4B 9.14B 8.17B 11.4B 9.07B 8.01B 10.8B 10B
Purchases of property, plant and equipment (USD) -748M -590M -924M -825M -650M -579M -728M -585M -523M -563M
Change in receivables (cash effect) (USD) 1.19B 754M 480M -218M -1.17B 313M -406M 157M 139M -367M
Change in inventories (cash effect) (USD) -488M -253M -310M -95M -195M 11M -310M -842M -426M -1.04B
Change in payables (cash effect) (USD) 47M -430M -39M -61M 80M -118M 226M -347M 290M -132M
Dividends paid (cash effect) (USD) -2.46B -2.73B -2.97B -3.22B -3.45B -3.61B -3.71B -3.81B -3.92B -4B
Share buybacks (cash effect) (USD) -11B -954M -2.9B -1.75B -1.58B -546M -1.4B -1B -1.15B -1.92B
Interest paid (cash effect) (USD) -885M -1.04B -1.07B -982M -951M -979M -907M -891M -951M -1.04B
Income taxes paid (cash effect) (USD) -2.44B -3.34B -3.2B -1.79B -2.64B -2.51B -3.14B -3.99B -2.78B -3.22B
Share-based compensation (USD) 380M 638M 845M 636M 643M 635M 637M 766M 835M 894M
Operating cash flow before change in receivables (USD) 15.5B 11.1B 7.92B 9.36B 9.34B 11.1B 9.48B 7.85B 10.7B 10.4B
Free cash flow (OCF - PPE - intangibles) (USD) 15.9B 11.3B 7.48B 8.32B 7.52B 10.8B 8.34B 7.42B 10.3B 9.46B
Income detail
Research and development expense (USD) 5.1B 3.73B 5.02B 9.11B 5.04B 5.36B 4.98B 5.72B 5.91B 5.8B
↳ 5y CAGR +32.9% +16.2% +18.8% +26.1% +10.8% +1.0% +5.9% +2.6% -8.3% +2.8%
Total comprehensive income (USD) 13.7B 4.53B 5.67B 5.37B -56M 6.34B 4.49B 5.64B 584M 8.42B
Comprehensive income to owners (USD) 13.7B 4.52B 5.66B 5.39B -22M 6.37B 4.51B 5.69B 584M 8.42B
Reported Feb 27, 2017 Feb 27, 2018 Feb 26, 2019 Feb 25, 2020 Feb 25, 2021 Feb 23, 2022 Feb 22, 2023 Feb 23, 2024 Feb 28, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 6, 2026

– Zero HIV Acquisitions Occurred Among Participants Receiving Twice-Yearly Lenacapavir During the 52-Week Study Period –

– PURPOSE 5 Study Findings Highlight the Potential of Long-Acting HIV Prevention Option to Address Persistence Challenges with Up to a Full Year of Protection After Second Dose –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- GileadSciences, Inc. (Nasdaq: GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting twice-yearly injectable lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP), compared with those starting daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). The trial included people in the United Kingdom (UK) and France who would benefit from PrEP. These data will be presented at HIV Glasgow 2026.

Key Highlights:

  • Twice-yearly lenacapavir achieved significantly higher one-year PrEP persistence than daily oral F/TDF, with 85.6% of participants receiving twice-yearly lenacapavir remaining persistent through Week 52 compared with 46.3% for participants taking once-daily F/TDF (p<0.0001).

  • PURPOSE 5 is the first randomized study specifically designed to compare persistence between a long-acting HIV prevention option and daily oral PrEP among individuals not currently taking PrEP.

  • Zero HIV acquisitions occurred among participants receiving twice-yearly lenacapavir during the 52-week study period.

  • Results highlight the potential of twice-yearly lenacapavir to address persistence challenges that can limit the effectiveness of HIV prevention efforts.

Despite substantial progress in HIV prevention, approximately 1.2 million people acquired HIV globally in 2025, according to UNAIDS, underscoring the need for prevention options that better support long-term use and protection. Persistence on PrEP remains one of the most important determinants of real-world prevention effectiveness. Daily oral F/TDF is currently the most commonly used oral PrEP medication globally.

“While starting on PrEP is important, persisting on PrEP is critical to preventing HIV acquisition,” said Professor Chloe Orkin, MBE, Clinical Professor of Infection and Inequities, Queen Mary University of London. “In PURPOSE 5, people in France and the United Kingdom receiving twice-yearly lenacapavir injections were much more likely to keep taking PrEP effectively compared with those receiving daily PrEP tablets. These findings suggest long-acting injections for PrEP may help address a very important barrier to sustained HIV prevention for people who need it. It is notable that the study was able to reach a high proportion of new PrEP users.”

“This study was designed specifically to evaluate one of the most important challenges in HIV prevention today: helping people remain on PrEP for as long as they need protection,” said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences. “These results demonstrate that twice-yearly lenacapavir has the potential to help close the gap between starting PrEP and staying on PrEP which can have an important impact on our efforts to end the HIV epidemic in Europe and around the world.”

PURPOSE 5 Results

PURPOSE 5 is an ongoing Phase 2, randomized, open-label study evaluating PrEP persistence among individuals with HIV prevention needs in the United Kingdom and France who were not taking PrEP at the time of enrollment. Participants were randomized 2:1 to receive either twice-yearly lenacapavir or daily oral F/TDF and were followed for 52 weeks.

A total of 267 participants enrolled in the study, including cisgender men (72.3%), cisgender women (7.1%) and gender-diverse individuals (20.6%). 37.8% were PrEP-naïve at baseline.

At Week 52:

  • 85.6% (154/180) of participants receiving twice-yearly lenacapavir remained persistent on PrEP

  • 46.3% (37/80) of participants receiving daily oral F/TDF remained persistent on PrEP

  • The difference of 39.3 (95% CI: 26.66% - 51.41%) was statistically significant ( p<0.0001)

Zero HIV acquisitions occurred among participants receiving lenacapavir. One HIV acquisition was reported in the F/TDF group; drug-level analysis at the time of diagnosis was consistent with fewer than two doses of F/TDF per week. Participant retention across both groups remained high throughout the study, with 89.4% of participants in the lenacapavir group and 83.9% of participants in the F/TDF group attending the Week 52 study visit.

For the purpose of this study Gilead used strict protocol definitions of persistence. For lenacapavir persistence was defined as receipt of on-time LEN injection at Day 1/baseline and week 26 (+/- 2 weeks) and on-time follow-up visit at week 52. For F/TDF persistence was defined as dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations consistent with ≥ 4 doses/week (≥ 700 fmol/punch) at Weeks 13, 26, 39, and 52.

Safety

The safety profile observed in PURPOSE 5 was generally consistent with previous studies of lenacapavir for HIV prevention. Serious adverse events were uncommon and occurred in 3.9% of participants receiving lenacapavir and 3.4% of participants receiving F/TDF. Investigators determined that no serious adverse events were related to study treatment. No participants discontinued treatment due to adverse events with lenacapavir. The most common treatment-related events were mild or moderate injection-site reactions (ISRs) associated with subcutaneous lenacapavir administration, and included nodules (67.8%), pain (60.0%), induration (20.6%), and erythema (17.8%).

Addressing a Critical HIV Prevention Challenge

Although awareness and availability of PrEP have increased, persistence remains a challenge across many settings. Daily oral PrEP is highly effective when taken as prescribed, but real-world studies have consistently shown that many individuals discontinue PrEP within the first year of use. By reducing dosing frequency to one dose every six months, twice-yearly lenacapavir has the potential to offer a discreet and convenient HIV prevention option that may better align with the needs and preferences of some individuals more vulnerable to HIV acquisition.

About PURPOSE 5

PURPOSE 5 is the first randomized study designed specifically to compare persistence between a long-acting injectable HIV prevention option and daily oral PrEP among individuals who would benefit from PrEP and were not currently taking oral PrEP. The Phase 2 study conducted in the United Kingdom and France evaluates whether twice-yearly lenacapavir can improve persistence compared with daily oral F/TDF over 52 weeks.

PURPOSE 5 is part of Gilead’s broader PURPOSE clinical development program evaluating lenacapavir across diverse populations and settings with the goal of expanding HIV prevention choice through long-acting prevention options.

About the PURPOSE Program

Gilead’s landmark PURPOSE program is the most comprehensive and diverse HIV prevention trial program ever conducted. The program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community engagement, and health equity.

The PURPOSE 1 and PURPOSE 2 trials evaluated the safety and efficacy of twice-yearly injectable lenacapavir to reduce the chance of getting HIV. The ongoing Phase 2 and 3 program, consisting of PURPOSE 1-5 studies, is assessing the potential of lenacapavir to help a diverse range of people around the world who could benefit from PrEP.

More information about the PURPOSE program, including individual trial descriptions, populations and locations, can be found at www.purposestudies.com.

About Lenacapavir

Twice-yearly lenacapavir is approved in multiple countries as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents who are at risk of HIV acquisition. Lenacapavir is also approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals.

The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.

Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program, including a once-yearly injection for HIV prevention. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV. The journal Science named lenacapavir its 2024 “Breakthrough of the Year.”

Indication for Yeytuo® (lenacapavir)

Yeytuo injection is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents with increased HIV-1 acquisition risk weighing at least 35kg.

Indication for Yeztugo® (lenacapavir)

Yeztugo is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35kg) who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Yeztugo.

Important Safety Information for Yeztugo

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO IN UNDIAGNOSED HIV-1 INFECTION

  • Individuals must be tested for HIV-1 infection prior to initiating Yeztugo, and with each subsequent injection of Yeztugo, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of Yeztugo by individuals with undiagnosed HIV-1 infection. Do not initiate Yeztugo unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving Yeztugo must transition to a complete HIV-1 treatment regimen.

Contraindications

  • Yeztugo is contraindicated in individuals with unknown or positive HIV-1 status.

Warnings and precautions

  • Comprehensive risk management:

  • Use Yeztugo to reduce the risk of HIV-1 acquisition as part of a comprehensive prevention strategy including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs).

  • HIV-1 acquisition risk includes behavioral, biological, or epidemiologic factors including, but not limited to, condomless sex, past or present STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high-prevalence area or network. Counsel individuals on the use of other prevention methods to help reduce their risk.

  • Use Yeztugo only in individuals confirmed to be HIV-1 negative. Evaluate for current or recent signs or symptoms consistent with HIV-1 infection. Confirm HIV-1 negative status prior to initiating, prior to each subsequent injection, and as clinically appropriate.

  • Potential risk of resistance:

  • There is a potential risk of developing resistance to Yeztugo if an individual acquires HIV-1 before or when receiving Yeztugo, or following discontinuation. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection taking only Yeztugo, because Yeztugo alone is not a complete regimen for HIV-1 treatment.

  • To minimize this risk, it is essential to test before each injection and additionally as clinically appropriate. Individuals confirmed to have HIV-1 must immediately begin a complete HIV-1 treatment regimen.

  • Alternative forms of PrEP should be considered after discontinuation of Yeztugo for those who are at continuing risk of HIV-1 acquisition and should be initiated within 28 weeks of the last Yeztugo injection.

  • Long-acting properties and potential associated risks:

  • Residual concentrations of Yeztugo may remain in systemic circulation for up to 12 months or longer after the last injection.

  • Select individuals who agree to the required injection dosing schedule because nonadherence or missed doses could lead to HIV-1 acquisition and development of resistance.

  • Serious injection site reactions: Improper administration (intradermal injection) has been associated with serious injection site reactions, including necrosis and ulcer. Only administer Yeztugo subcutaneously.

Adverse reactions

  • Most common adverse reactions(≥5%) in Yeztugo clinical trials were injection site reactions, headache, and nausea.

Drug interactions

  • Strong or moderate CYP3A inducers may significantly decrease Yeztugo concentrations. Dosage modifications are recommended when initiating these inducers.

  • It is not recommended to use Yeztugo with combined P-gp, UGT1A1, and strong CYP3A inhibitors.

  • Coadministration of Yeztugo with sensitive substrates of CYP3A or P-gp may increase their concentrations and result in the increased risk of their adverse events. Yeztugo may increase the exposure of drugs primarily metabolized by CYP3A initiated within 9 months after the last injection of Yeztugo.

Dosage and administration

  • HIV screening: Test for HIV-1 infection prior to initiating, prior to each subsequent injection, and as clinically appropriate using an approved or cleared test for the diagnosis of acute or primary HIV-1 infection.

  • Dosage: Initiation dosing (injections and tablets) followed by once-every-6-months continuation injection dosing. Tablets may be taken with or without food.

  • Initiation: Day 1: 927 mg by subcutaneous injection (2 x 1.5-mL injections) and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally.

  • Continuation: 927 mg by subcutaneous injection every 6 months (26 weeks) from date of last injection ±2 weeks.

  • Anticipated delayed injections: If scheduled 6-month injection is anticipated to be delayed by more than 2 weeks, Yeztugo tablets may be taken on an interim basis (for up to 6 months) until injections resume. Dosage is 300 mg orally (1 x 300-mg tablet) once every 7 days. Resume continuation injections within 7 days of the last oral dose.

  • Missed injections: If more than 28 weeks have elapsed since the last injection and Yeztugo tablets have not been taken, restart with initiation dosing if clinically appropriate.

  • Dosage modifications of Yeztugo are recommended when initiating with strong or moderate CYP3A inducers. Consult the full Prescribing Information for recommendations.

About Gilead HIV

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 14 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people.

Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic worldwide. Gilead has been repeatedly recognized as one of the top two leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS.

Discover more about Gilead’s unique collaborations worldwide and the work to help end the HIV epidemic.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving lenacapavir (such as PURPOSE 5); uncertainties relating to regulatory applications and related filing and approval timelines, including regulatory applications for lenacapavir for PrEP, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of lenacapavir for indications currently under evaluation and, as a result, lenacapavir may never be successfully commercialized for such indications; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

U.S. full Prescribing Information for Truvada (F/TDF) and Yeztugo, including Boxed Warning, are available at www.gilead.com.

Gilead and the Gilead logo, Truvada, Yeztugo and Yeytugo are registered trademarks of Gilead Sciences, Inc., or its related companies.

November 5, 2026

- Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67**×**ULN, Despite Receiving UDCA or with Intolerance to UDCA -

- Gilead Will Engage Global Regulatory Authorities Based on These Results -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. These results can expand understanding of treatment effects and inform evolving treatment goals for people living with PBC.

Key Highlights

  • At Week 52, 75.4% (49/65) of participants who received Livdelzi achieved the ALP normalization composite endpoint versus 16.1% (5/31) of participants receiving placebo.

  • Results will be presented at The Liver Meeting ® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado, and have been accepted for upcoming publication in the Journal of Hepatology.

  • Gilead is engaging with global regulatory authorities to discuss these results.

IDEAL is a Phase 3, randomized, double‑blind, placebo‑controlled clinical study evaluating Livdelzi in adults living with PBC who have ALP levels above normal yet below the 1.67× ULN threshold typically required for inclusion in other PBC randomized controlled trials (RCTs). It is the first clinical trial to evaluate Livdelzi in people with inadequately controlled disease defined as ALP levels of 1-1.67× ULN despite receiving ursodeoxycholic acid (UDCA) for 12 months or with intolerance to UDCA.

“People with PBC whose alkaline phosphatase remains elevated but below 1.67 times the upper limit of normal have been largely excluded from previous pivotal trials of second-line therapies,” said Cynthia Levy, MD, University of Miami Miller School of Medicine. “IDEAL provides randomized, placebo-controlled evidence that seladelpar can improve biochemical response in this population. These findings can inform individualized treatment discussions, taking into account each individual’s risk of disease progression, symptoms, and potential benefits and risks of additional therapy.”

ALP is a key marker of disease activity with levels above normal associated with an increased risk of disease progression and poorer long-term outcomes, such as liver failure. Historically, the threshold for clinical study inclusion has been ALP levels >1.67× ULN. Recent clinical guidance recognizes ALP normalization as an ideal treatment goal in PBC. Results from IDEAL expand the evidence base by demonstrating that a significantly higher proportion of people with baseline ALP levels between 1-1.67× ULN and treated with Livdelzi can achieve ALP normalization compared to placebo. The response was evident after one month of treatment (52.3% versus 6.5% receiving placebo) and sustained through Week 52.

“The IDEAL study evaluated the impact of initiating second-line treatment in people living with PBC who have lower levels of baseline ALP elevation compared to prior clinical trials,” said Swati Tole, MD, MS, Senior Vice President, Clinical Development, Inflammation, Gilead Sciences. “A significantly greater proportion of people with elevated ALP levels, but below the threshold typically studied, achieved ALP normalization with Livdelzi, supporting ALP normalization as an achievable treatment goal. Together with the broader Livdelzi clinical program, IDEAL reinforces the importance of continuing to raise expectations for PBC care across a wide range of patients.”

The safety profile of Livdelzi observed in IDEAL was consistent with previously reported Livdelzi studies, with no new safety concerns identified. Adverse event incidence was generally similar between Livdelzi and placebo groups; serious adverse events occurred in 3.1% and 12.9% of individuals, respectively, and none were deemed related to trial drug.

About IDEAL (NCT06060665)

The IDEAL study was a Phase 3, double‑blind, placebo‑controlled trial designed to evaluate Livdelzi in adults living with primary biliary cholangitis (PBC) who have inadequately controlled disease, defined as having alkaline phosphatase (ALP) levels above normal but less than 1.67× ULN despite treatment with ursodeoxycholic acid (UDCA) or with UDCA intolerance. Its primary objective was to evaluate the effect of Livdelzi treatment at Week 52 compared to placebo, assessing rates of ALP normalization, defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with an ALP value greater than ULN but less than 1.67× ULN. A composite was used for the primary endpoint to ensure rigorous evaluation of ALP normalization over time. Exploratory endpoints included changes in other markers of cholestasis and liver injury. The study also evaluated the safety and tolerability of Livdelzi compared with placebo through Week 52. The study enrolled 96 adults aged 18–75 years.

About PBC

PBC is a chronic, autoimmune disease of the bile ducts that affects approximately 130,000 Americans. PBC is more common in women and causes liver damage that can progress to liver failure and result in the need for liver transplant, if left untreated. The most common symptoms of PBC are pruritus (chronic itch) and fatigue, which up to 80% of people living with PBC can experience and can profoundly compromise quality of life. Symptoms of PBC are often invisible to others and the journey to a PBC diagnosis can be long and challenging.

There is currently no cure for PBC, and treatment goals include reducing the risk of disease progression and reducing the symptoms related to cholestasis (impaired bile flow), such as cholestatic itch. The effect is primarily measured by an improvement in liver biochemical tests, including the improvement and normalization of alkaline phosphatase (ALP) levels, an important marker associated with long‑term outcomes in PBC.

About Livdelzi

Livdelzi (seladelpar) is an oral PPAR‑delta agonist, or delpar, for the treatment of primary biliary cholangitis (PBC). PPAR‑delta is known to regulate key metabolic and liver disease pathways. Preclinical and clinical data indicate that Livdelzi has potential anticholestatic, anti‑inflammatory, antipruritic, and antifibrotic effects.

Clinical trial data demonstrate that Livdelzi supports meaningful improvements in key markers of disease activity, including biochemical response and alkaline phosphatase (ALP) normalization, with sustained effects observed over long‑term follow‑up in multiple studies. These findings are supported by clinical studies evaluating Livdelzi in participants treated for up to 5 years.

Livdelzi has the potential to help address ongoing unmet needs for people living with PBC, including those who remain inadequately controlled on existing therapies. Pruritus is one of the most common and debilitating symptoms of PBC that can significantly impair quality of life. Clinical trial data have demonstrated improvements in pruritus with Livdelzi compared with placebo.

U.S. Indication for Livdelzi

Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. The FDA approved this indication under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Limitations of Use:

Use of Livdelzi is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

U.S. Important Safety Information for LIVDELZI

Warnings and Precautions

  • Fractures: Fractures occurred in 4% of LIVDELZI-treated patients compared to no placebo-treated patients. Consider the risk of fracture in the care of patients treated with LIVDELZI and monitor bone health according to current standards of care.

  • Liver Test Abnormalities: LIVDELZI has been associated with dose-related increases in serum transaminase (AST and ALT) levels > 3 x ULN in patients receiving 50 mg and 200 mg once daily (5x and 20x higher than the recommended dosage of 10 mg once daily). Perform baseline clinical and laboratory testing when starting LIVDELZI and monitor thereafter according to routine patient management. Interrupt treatment if the liver tests (ALT, AST, total bilirubin, and/or ALP) worsen, or if the patient develops signs and symptoms of clinical hepatitis (e.g., jaundice, right upper quadrant pain, eosinophilia). Consider permanent discontinuation if liver tests worsen after restarting LIVDELZI.

  • Biliary Obstruction: Avoid use of LIVDELZI in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt LIVDELZI and treat as clinically indicated.

Adverse Reaction

  • The most common adverse reactions (≥5%) with LIVDELZI were headache (8%), abdominal pain (7%), nausea (6%), abdominal distension (6%), and dizziness (5%).

Drug Interactions

Potential Increased Exposure of LIVDELZI with:

  • Probenecid: Avoid coadministration with LIVDELZI.

  • Strong CYP2C9 Inhibitors: Monitor for adverse effects during concomitant use.

  • Dual Moderate CYP2C9 and Moderate or Strong CYP3A4 Inhibitors (e.g., fluconazole): Monitor for adverse effects during concomitant use.

  • CYP2C9 Poor Metabolizers Using Moderate or Strong CYP3A4 Inhibitors: Monitor for adverse effects during concomitant use of a moderate or strong CYP3A4 inhibitor in patients who are CYP2C9 poor metabolizers.

  • Dual or Multiple Clinical Inhibitors of Drug Transporters OATP1B1, OATP1B3, and BCRP (e.g., cyclosporine): Monitor for adverse effects during concomitant use.

Potential Reduction in LIVDELZI Exposure with:

  • Rifampin: Concomitant use of LIVDELZI with rifampin, an inducer of metabolizing enzymes, may result in delayed or suboptimal LIVDELZI biochemical response. Monitor biochemical response (e.g., ALP and bilirubin) when patients initiate rifampin during LIVDELZI treatment.

  • Bile Acid Sequestrants: Administer LIVDELZI at least 4 hours before or 4 hours after taking a bile acid sequestrant, or at as great an interval as possible.

Pregnancy and Lactation

  • Pregnancy: There are insufficient data from human pregnancies exposed to LIVDELZI to allow an assessment of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Gilead Sciences, Inc., at 1-800-445-3235.

  • Lactation: There are no data on the presence of LIVDELZI in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LIVDELZI and any potential adverse effects on the breastfed infant from LIVDELZI.

About Gilead Sciences in Liver Disease

For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. We have helped to transform hepatitis C from a chronic condition into one that can be cured for millions of people. For individuals living with hepatitis B or D, Gilead's focus on advancing medicines drives hope that today’s research will turn into tomorrow’s cures. Beyond viral hepatitis, Gilead is working to deliver advanced treatments for people living with PBC. But our commitment doesn’t stop there. Through ground-breaking science and collaborative partnerships, we strive to create healthier futures for everyone living with liver disease. Gilead remains committed to a future without liver disease.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation.

In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Livdelzi (seladelpar) (such as IDEAL); uncertainties relating to regulatory applications and related filing and approval timelines, including additional pending and potential applications for seladelpar; the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Livdelzi, Lyvdelzi, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

U.S. full Prescribing Information for Livdelzi® is available at www.gilead.com.

November 4, 2026

– iMMagine-1 Data Provide 18 Months Minimum Follow-Up on Anito-cel’s Durability and Safety in Relapsed or Refractory Multiple Myeloma –

– Five-Year ZUMA-12 Follow-Up Data to Provide Long-Term Evidence for Yescarta®in First-Line High-Risk Large B-cell Lymphoma –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026).

These latest clinical milestones demonstrate transformative progress across Gilead and Kite’s pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or refractory (RR) multiple myeloma (MM), to early clinical results from our next-generation approaches in lymphoma and autoimmune blood disorders, and long-term follow-up data supporting standard-of-care therapies.

"People living with blood cancers deserve treatments that offer more than a response; they deserve the possibility of lasting freedom from disease,” said Gallia Levy, MD, PhD, Senior Vice President, Global Head of Development at Kite. “The data we are presenting reflect the breadth of our leadership and our commitment to advancing next-generation cell therapy, so more patients can benefit across multiple cancers and throughout their treatment journey."

Key presentations at ASH 2026

**Deepening and Expanding Clinical Evidence for Anito-cel in MM:Anito-cel is an investigational CAR T-cell therapy for the treatment of RRMM. At ASH, Kite will present 18-month minimum follow-up results from the pivotal Phase 2 iMMagine-1 open-label, single-arm, multicenter study of anito-cel in people who received three or more prior lines of therapy,**including treatments from all three major drug classesfor MM, alongside new comparative and collaborative research in the disease.

  • iMMagine-1 (4L+ RRMM): Maturing efficacy data, including progression-free survival (PFS) and overall survival (OS) analyses, alongside updated safety outcomes, from the pivotal Phase 2 open-label, single-arm study of anito-cel in RRMM. Data from the iMMagine-1 trial are the basis of the U.S. Food and Drug Administration (FDA) Biologics License Application (BLA) submission, which is under review with a Prescription Drug User Fee Act (PDUFA) target date of December 23, 2026.

  • Comparative Analyses (RRMM): New matching-adjusted indirect comparison (MAIC) analyses examining the efficacy and safety of anito-cel versus bispecific antibodies and other CAR T-cell therapies.

  • GEM-AnitoFIRST (Newly Diagnosed MM): Data from the open-label, non-randomized Phase 2 study being conducted in collaboration with the PETHEMA Foundation (Programa Español de Tratamiento en Hematología) evaluating anito-cel in newly diagnosed MM.

Expanding Real-World Use and Long-Term Evidence Underscore the Track Record for Yescarta®:

  • ZUMA-12 (1L High-Risk LBCL): Five-year follow-up from the first prospective Phase 2, single-arm, open-label study evaluating Yescarta ®(axicabtagene ciloleucel) as a first-line treatment for high-risk large B-cell lymphoma (LBCL) patients who remain positron emission tomography (PET)-positive after two cycles of chemoimmunotherapy.

  • Real-World Evidence: Expanding real-world data, including outcomes from the French collaborative group The Lymphoma Study Association/Lymphoma Academic Research Organization (LYSA/LYSARC) (DESCAR-T) registry across established and newly authorized treatment centers, and Canadian data assessing the feasibility and safety of outpatient CAR T administration.

  • GELTAMO LATE-R: Second interim analysis of the Phase 2, single-arm, open-label study of axicabtagene ciloleucel in patients with late-relapsing LBCL after completing first-line chemoimmunotherapy (CIT).

**Initial Global Clinical Experience with Investigational Gamgertamig (CM336/OM336) in Relapsed/Refractory Autoimmune Cytopenias (AICs):**Gilead and Lakefront Biotherapeutics (Lakefront) are collaborating to advance programs in inflammation, including the development of gamgertamig (CM336/OM336), an investigational BCMAxCD3 bispecific T cell engager for the treatment of autoantibody-driven, immune-mediated disease. New data from two ongoing Phase 1b studies will provide initial clinical experience with short-course subcutaneous gamgertamig, administered over a maximum of three weeks in people with relapsed or refractory AICs.

  • Immune Thrombocytopenia (ITP): Response, time-to-response and durability data across three dose cohorts in people with relapsed or refractory ITP, a rare autoantibody-driven disease that causes platelet destruction and increased bleeding risk.

  • Autoimmune Hemolytic Anemia (AIHA): Response, time-to-response and durability data across three dose cohorts in people with relapsed or refractory AIHA, a rare autoantibody-driven disease that causes destruction of red blood cells leading to anemia.

Dates and times are listed in CT for the following accepted abstracts and presentations:

| Abstract Details | Titles |

| Oral Presentations |

| Anitocabtagene Autoleucel |

| Abstract #273 Saturday, December 12 2:30 – 2:45 PM MCCNO – La Nouvelle C | Updated Analysis of iMMagine-1, a Phase 2 Registrational Study of Anitocabtagene Autoleucel (Anito-cel) for the Treatment of Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) |

| Abstract #6579 Saturday, December 12 9:30 – 9:45 AM MCCNO – Hall E | Anitocabtagene Autoleucel Following Induction Therapy in Newly Diagnosed Multiple Myeloma: Early Safety, Response, and MRD Results from the Phase 2 GEM-AnitoFIRST Study* Collaboration with PETHEMA Foundation |

| Axicabtagene Ciloleucel |

| Abstract #1031 Monday, December 14 5:30 – 5:45 PM MCCNO – New Orleans Theatre A | Axicabtagene Ciloleucel as Second-line Treatment for Late-relapsed Aggressive Large B-cell Lymphoma: Second Interim Analysis of the GELTAMO LATE-R Phase II Trial* Collaboration with GELTAMO |

| Abstract #614 Saturday, December 12 12:15 – 12:30 PM MCCNO – New Orleans Theatre C | Real-world Outcomes After Axicabtagene Ciloleucel as 2nd- vs 3rd-line Therapy in Large B-cell Lymphoma: A Propensity Score-matched Analysis from the French DESCAR-T Registry* Collaboration with LYSA/LYSARC |

| Abstract #613 Sunday, December 13 12:00 – 12:15 PM MCCNO – New Orleans Theatre C | A Prospective Clinical Trial of Comprehensive Ablative Bridging Irradiation (CABI) Prior to Axicabtagene Ciloleucel for Relapsed or Refractory Large B Cell Lymphoma |

| Abstract #703 Sunday, December 13 4:30 – 4:45 PM MCCNO – New Orleans Theatre B | Double-dose Axicabtagene Ciloleucel (Axi-Cel-2) as Second-line Therapy for High-risk Relapsed or Refractory Large B-cell Lymphoma: Results from the Phase 1b ENCORE-1 Trial |

| Additional CAR T-Cell Therapy |

| Abstract #1056 Monday, December 14 5:45 – 6:00 PM MCCNO – 388-390 | Armored TmCD19-IL18 CAR T cells in patients with CD19+ lymphomas |

| Poster Presentations |

| Anitocabtagene Autoleucel |

| Abstract #4042 Sunday, December 13 6:00 – 8:00 PM MCCNO – Hall F | Matching-Adjusted Indirect Comparisons (MAICs) of Anitocabtagene Autoleucel (anito-cel) vs Teclistamab and Talquetamab for the Treatment of 4L+ Relapsed and/or Refractory Multiple Myeloma (RRMM): Analysis with Extended iMMagine-1 Follow-up |

| Abstract #4043 Sunday, December 13 6:00 – 8:00 PM MCCNO – Hall F | Matching-Adjusted Indirect Comparisons (MAICs) of Efficacy and Safety Outcomes for Anitocabtagene Autoleucel Versus Ciltacabtagene Autoleucel in 4L+ Relapsed and/or Refractory Multiple Myeloma (RRMM): Analysis with Extended iMMagine-1 Follow-up |

| KITE-753 |

| Abstract #5944 Monday, December 14 6:00 – 8:00 PM MCCNO – Hall F | Response Durability and Early Immune Cell Recovery: Updated Results from the Phase 1 Multicenter PALISADES-1 Study of KITE-753 in Relapsed/Refractory B-cell Lymphoma |

| Axicabtagene Ciloleucel |

| Abstract #1912 Saturday, December 12 5:30 – 7:30 PM MCCNO – Hall F | 5-year Follow-up of the Phase 2 ZUMA-12 Study of Axicabtagene Ciloleucel (Axi-cel) as First-line Therapy in Patients (Pts) with High-risk Large B-cell Lymphoma (LBCL) |

| Abstract #2632 Saturday, December 12 5:30 – 7:30 PM MCCNO – Hall F | Feasibility of Outpatient Axicabtagene Ciloleucel (Axi-cel) for Relapsed/Refractory Large B-Cell Lymphoma: A Single-Centre Analysis in Canada |

| Abstract #2728 Saturday, December 12 5:30 – 7:30 PM MCCNO – Hall F | Audit of the Uptake of Second Line Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma in the Welsh Population with Assessment of the Impact of Deprivation onAccess to and Response Following First Line Chemoimmunotherapy |

| | Impact of Fludarabine Exposure Levels During Lymphodepletion on the Efficacy and Toxicity of Axicabtagene Ciloleucel in Large B-cell Lymphoma: A Multicenter Retrospective Study |

| Brexucabtagene Autoleucel |

| Abstract #5081 Monday, December 14 6:00 – 8:00 PM MCCNO – Hall F | Brexucabtagene Autoleucel as Consolidation Therapy in Adult Patients with High-risk Philadelphia (Ph)-negative B-cell Acute Lymphoblastic Leukemia |

| | Real-world outcomes after second CD19-directed CAR T cell treatment for relapsed/refractory B cell acute lymphoblastic leukemia |

| | CD19-directed CAR T-cell therapy with brexucabtagene autoleucel or obecabtagene autoleucel produces durable remission for CML patients in lymphoid blast phase: A Rocca consortium multicenter analysis |

| | High Efficacy of Obe-cel and Brexu-cel in Patients with Extramedullary B-ALL |

| Additional CAR T-Cell Therapy |

| Abstract #4107 Sunday, December 13 6:00 – 8:00 PM MCCNO – Hall F | Depth of Lymphodepletion, Measured by IL-15 Serum Levels, as a Modifiable Risk Factor for Neurotoxicity and Non-relapse Mortality: Results from Large-scale Protein Screening Across 710 Patients Treated with Anti-CD19 CAR T Cell Therapy |

| | Access to CAR T cell therapy for adults with multiple myeloma or large B-cell lymphoma: Patient, caregiver, and clinician perspectives |

| Gamgertamig |

| Abstract #3008 Sunday, December 13 6:00 – 8:00 PM MCCNO – Hall F | Initial global clinical experience with gamgertamig (CM336/OM336), a BCMAxCD3 T‑cell engager, in relapsed/refractory autoimmune cytopenias (AICs) in two parallel ongoing studies (NCT07083960, NCT07175493)* Collaboration with Lakefront |

| Publication Only |

| Abstract #7562 | Real-world (RW) Outcomes of Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-cel) in Non-Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) Accredited Centers in France from the DESCAR-T Registry |

*Kite collaborative or investigator-initiated studies

For remaining presentation information, please visit: https://www.hematology.org/Meetings/Annual-Meeting

About Yescarta & Tecartus

YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel) are genetically modified autologous T-cell immunotherapies that use a patient’s own T cells, which are modified ex vivo to express a chimeric antigen receptor (CAR) designed to recognize CD19. The anti-CD19 CAR T cells are expanded and infused back into the patient, where they recognize and kill CD19-expressing target cells.

U.S. Indications for YESCARTA and TECARTUS

YESCARTA is indicated for the treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy; adult patients with relapsed or refractory (R/R) LBCL after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma; and adult patients with R/R follicular lymphoma (FL) after two or more lines of systemic therapy. The FL indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial.

TECARTUS is indicated for the treatment of adult patients with R/R mantle cell lymphoma (MCL) and adult patients with R/R B-cell precursor acute lymphoblastic leukemia (ALL).

U.S. Important Safety Information for YESCARTA and TECARTUS

BOXED WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES and SECONDARY HEMATOLOGICAL MALIGNANCIES

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA or TECARTUS. Do not administer YESCARTA or TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.

  • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA or TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA or TECARTUS. Provide supportive care and/or corticosteroids as needed.

  • T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including YESCARTA.

YESCARTA Warnings and precautions

  • Serious hypersensitivity reactions may occur during YESCARTA infusion. Monitor patients for hypersensitivity reactions during infusion.

  • Severe or life-threatening infections occurred in patients after YESCARTA infusion. Infections (all grades) occurred in 45% of patients with NHL. Grade 3 or higher infections occurred in 17% of patients, including Grade 3 or higher infections with an unspecified pathogen in 12%, bacterial infections in 5%, viral infections in 3%, and fungal infections in 1%. YESCARTA should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after YESCARTA infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines. Febrile neutropenia was observed in 36% of patients with NHL after YESCARTA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated. In immunosuppressed patients, including those who have received YESCARTA, life-threatening and fatal opportunistic infections including disseminated fungal infections have been reported. The possibility of HHV-6 encephalitis and PML should be considered in immunosuppressed patients with neurologic events and appropriate diagnostic evaluations should be performed. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with drugs directed against B cells, including YESCARTA. Perform screening for HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing.

  • Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and YESCARTA infusion. Grade 3 or higher cytopenias not resolved by Day 30 following YESCARTA infusion occurred in 39% of all patients with NHL and included neutropenia (33%), thrombocytopenia (13%), and anemia (8%). Monitor blood counts after YESCARTA infusion.

  • Hypogammaglobulinemia: B-cell aplasia and hypogammaglobulinemia can occur in patients receiving treatment with YESCARTA. Hypogammaglobulinemia was reported as an adverse reaction in 14% of all patients with NHL. Monitor immunoglobulin levels after treatment with YESCARTA and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement.

  • Secondary Malignancies: Patients treated with YESCARTA may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including YESCARTA. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Kite at 1-844-454-KITE (5483).

YESCARTA Adverse reactions

  • The most common adverse reactions (incidence ≥ 30%), excluding laboratory abnormalities, in patients with non-Hodgkin lymphoma are CRS, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections with pathogen unspecified, chills and decreased appetite. The most common Grade 3-4 laboratory abnormalities (≥ 30%) are leukopenia, lymphopenia, neutropenia, anemia, thrombocytopenia, and hypophosphatemia.

YESCARTA Dosage and administration

For autologous use only. For intravenous use only.

  • Dosing of YESCARTA is based on the number of chimeric antigen receptor (CAR)-positive viable T cells. The target YESCARTA dose is 2 × 10 6 CAR-positive viable T cells per kg body weight, with a maximum of 2 × 10 8 CAR-positive viable T cells.

  • Pretreatment: Administer a lymphodepleting chemotherapy regimen of cyclophosphamide 500 mg/m 2 intravenously and fludarabine 30 mg/m 2 intravenously on the fifth, fourth, and third day before infusion of YESCARTA.

  • Premedication: Premedicate with acetaminophen and an H1-antihistamine.

  • Confirm availability of tocilizumab and****verify the patient’s identity prior to infusion.

  • Do NOT use a leukodepleting filter.

  • Infuse the entire contents of the YESCARTA bag within 30 minutes of thawing by either gravity or a peristaltic pump. YESCARTA is stable at room temperature for up to 3 hours after thaw.

TECARTUS Warnings and precautions

  • Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including life-threatening reactions, occurred following treatment with TECARTUS. HLH/MAS occurred in 4% (3/78) of patients with ALL. Two patients experienced Grade 3 events, and 1 patient experienced a Grade 4 event. All 3 patients with HLH/MAS had concurrent CRS symptoms and neurologic events after TECARTUS infusion. Treatment of HLH/MAS should be administered per institutional standards.

  • Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide or residual gentamicin in TECARTUS.

  • Severe or life-threatening infections occurred in patients after TECARTUS infusion. Infections (all grades) occurred in 63% (105/168) of patients with MCL and 44% (34/78) of patients with ALL. Grade 3 or higher infections, including bacterial, viral, and fungal infections, occurred in 33% of patients with MCL and 29% of patients with ALL. TECARTUS should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after TECARTUS infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines. Febrile neutropenia was observed in 4% of patients with MCL and 35% of patients with ALL after TECARTUS infusion and may be concurrent with CRS. The febrile neutropenia in 27 (35%) patients with ALL includes events of “febrile neutropenia” (11 (14%)) plus the concurrent events of “fever” and “neutropenia” (16 (21%)). In the event of febrile neutropenia, evaluate for infection and manage with broad spectrum antibiotics, fluids, and other supportive care as medically indicated. In immunosuppressed patients, life-threatening and fatal opportunistic infections have been reported. The possibility of rare infectious etiologies should be considered in patients with neurologic events and appropriate diagnostic evaluations should be performed. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing.

  • Prolonged Cytopenias: Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and TECARTUS infusion. In patients with MCL, Grade 3 or higher cytopenias not resolved by Day 30 following TECARTUS infusion occurred in 55% (92/168) of patients and included thrombocytopenia (32%), neutropenia (42%), and anemia (14%). In patients with ALL who were responders to TECARTUS treatment, Grade 3 or higher cytopenias not resolved by Day 30 following TECARTUS infusion occurred in 20% (7/35) of the patients and included neutropenia (12%) and thrombocytopenia (12%); Grade 3 or higher cytopenias not resolved by Day 60 following TECARTUS infusion occurred in 11% (4/35) of the patients and included neutropenia (9%) and thrombocytopenia (6%). Monitor blood counts after TECARTUS infusion.

  • Hypogammaglobulinemia: B cell aplasia and hypogammaglobulinemia can occur in patients receiving treatment with TECARTUS. Hypogammaglobulinemia was reported in 14% (23/168) of patients with MCL and 9% (7/78) of patients with ALL. Monitor immunoglobulin levels after treatment with TECARTUS and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement.

  • Secondary Malignancies: Patients treated with TECARTUS may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Kite at 1-844-454-KITE (5483).

TECARTUS Adverse reactions

  • The most common non-laboratory adverse reactions (incidence ≥ 20%) are:

  • MCL: CRS, fever, encephalopathy, hypotension, infection with pathogen unspecified, viral infections, fatigue, tachycardias, chills, hypoxia, tremor, cough, musculoskeletal pain, nausea, edema, headache, constipation, diarrhea, decreased appetite, dyspnea, rash, insomnia, pleural effusion, aphasia, motor dysfunction.

  • ALL: fever, CRS, hypotension, encephalopathy, tachycardia, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.

TECARTUS Dosage and administration

For autologous use only. For intravenous use only.

  • Dosing of TECARTUS is based on the number of chimeric antigen receptor (CAR)-positive viable T cells.

  • MCL: The target TECARTUS dose is 2 × 10 6 CAR-positive viable T cells per kg body weight, with a maximum of 2 × 10 8 CAR-positive viable T cells.

  • Pretreatment: Administer a lymphodepleting chemotherapy regimen of cyclophosphamide 500 mg/m 2 intravenously and fludarabine 30 mg/m 2 intravenously on the fifth, fourth, and third day before infusion of TECARTUS.

  • ALL: The target TECARTUS dose is 1 × 10 6 CAR-positive viable T cells per kg body weight, with a maximum of 1 × 10 8 CAR-positive viable T cells.

  • Pretreatment: Administer a lymphodepleting chemotherapy regimen of fludarabine 25 mg/m 2 intravenously over 30 minutes on the fourth, third, and second day and administer cyclophosphamide 900 mg/m 2 over 60 minutes on the second day before infusion of TECARTUS.

  • Premedication: Premedicate with acetaminophen and an H1-antihistamine.

  • Confirm availability of tocilizumab and****verify the patient’s identity prior to infusion.

  • Do NOT use a leukodepleting filter.

  • Infuse the entire contents of the TECARTUS bag within 30 minutes of thawing by either gravity or a peristaltic pump. TECARTUS is stable at room temperature for up to 3 hours after thaw.

U.S. Full Prescribing Information for YESCARTA and TECARTUS, including BOXED WARNINGS, are available at www.kitepharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

About Gilead and Kite Oncology

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

About Anitocabtagene autoleucel (anito-cel)

Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes a novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration.

About KITE-753

KITE-753 is an investigational, autologous bicistronic CAR T-cell therapy being evaluated for the treatment of adult patients with relapsed or refractory B-cell lymphoma. Designed to engage two established B-cell targets simultaneously (CD19 and CD20), KITE-753 also combines dual co-stimulatory signaling (CD28 and 4-1BB) to help T-cells respond quickly and stay active over time. Its T-cell optimized manufacturing process is intended to preserve T-cell fitness and enhance durability of complete responses.

About Gamgertamig (CM336/OM336)

Gamgertamig (CM336/OM336) is an investigational BCMAxCD3 bispecific T cell engager for the treatment of autoantibody-driven immune-mediated disease. It has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration for certain autoimmune diseases. Gamgertamig is under an open Investigational New Drug (IND) in the U.S. and is expected to enter registrational studies in 2027. Gamgertamig is being developed in collaboration with Lakefront Biotherapeutics.

Forward-Looking Statements

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical studies, including those involving Tecartus (brexucabtagene autoleucel), Yescarta (axicabtagene ciloleucel), anito-cel, gamgertamig, and KITE-753 (such as iMMagine-1, GEM-AnitoFIRST, LATE-R, and ZUMA-12); uncertainties relating to regulatory applications and related filing and approval timelines, including pending or potential applications for indications currently under evaluation, such as the BLA for anito-cel in RRMM; the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead and Kite may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

Yescarta, Tecartus, Gilead, the Gilead logo, Kite, and the Kite logo are trademarks of Gilead Sciences, Inc., or its related companies.

U.S. Prescribing Information for Yescarta and Tecartus, including BOXED WARNINGS, is available at www.kitepharma.com.

Prompts

Gilead Sciences, Inc. (ticker GILD), listed in United States.

Company History

Date Change Detail
Feb 28, 2024 Acquired Acquired Cymabay Therapeutics, Inc. (CIK 1042074). Its filings from before the deal are on its own company page, not shown here.
Nov 14, 2011 Acquired Acquired Pharmasset Inc (CIK 1301081). Its filings from before the deal are on its own company page, not shown here.
Nov 6, 2006 Acquired Acquired Myogen Inc (CIK 1101052). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Gilead Sciences, Inc.

ETF Weight in ETF Shares Market value As of
BMED 5.89% 5,033 $ 843.43K Nov 16, 2026
TMED 4.44% 8,084 $ 1.021M Jun 30, 2026
PINK 3.94% 77,477 $ 13.191M Nov 17, 2026
NEWZ 3.34% 4,079 $ 690K Nov 18, 2026
TBG 3.19% 62,462 $ 10.63M Nov 18, 2026
CVGD 3.15% 33,499 $ 4.362M Jul 31, 2026
HRTS 3.13% 11,884 $ 1.739M Aug 31, 2026
JPEF 3.05% 346,502 $ 58.995M Nov 17, 2026
CARK 2.97% 72,712 $ 9.468M Jul 31, 2026
GDIV 2.70% 38,842 $ 6.529M Nov 13, 2026
SELV 2.52% 48,801 $ 6.166M Jun 30, 2026
DIVN 2.50% 52,309 $ 7.655M Aug 31, 2026
CLCV 2.41% 3,169 $ 412.635K Jul 31, 2026
GEND 2.39% 891 $ 116.017K Jul 31, 2026
LOTI 2.25% 8,098 $ 1.054M Jul 31, 2026
PRMR 2.23% 13,949 $ 2.041M Aug 31, 2026
JDVL 2.22% 154,598 $ 19.532M Jun 30, 2026
BAMV 2.21% 17,443 $ 2.553M Aug 31, 2026
TOLL 2.13% 8,536 $ 1.249M Aug 31, 2026
UDI 2.13% 684 $ 86.417K Jun 30, 2026
LOWV 1.99% 27,778 $ 4.065M Aug 31, 2026
SAGP 1.95% 11,803 $ 1.491M Jun 30, 2026
CLCG 1.73% 3,757 $ 489.199K Jul 31, 2026
BAMD 1.68% 11,332 $ 1.658M Aug 31, 2026
VFQY 1.54% 53,896 $ 7.887M Aug 31, 2026
FBCV 1.53% 20,787 $ 2.707M Jul 31, 2026
ABFL 1.51% 61,154 $ 7.963M Jul 31, 2026
FFLV 1.49% 1,885 $ 245.446K Jul 31, 2026
FTHI 1.49% 224,663 $ 37.649M Nov 16, 2026
AVIE 1.46% 1,444 $ 241.986K Nov 16, 2026
FTQI 1.46% 83,383 $ 13.973M Nov 16, 2026
OZEM 1.45% 4,756 $ 809.757K Nov 17, 2026
DUHP 1.43% 1,662,461 $ 279.21M Nov 12, 2026
BRIF 1.38% 16,829 $ 2.126M Jun 30, 2026
TVAL 1.38% 93,962 $ 15.746M Nov 17, 2026
ACVU 1.36% 22,212 $ 0.00 Nov 18, 2026
TCAL 1.34% 26,466 $ 4.435M Nov 17, 2026
SIXA 1.31% 44,488 $ 7.472M Nov 12, 2026
BGRO 1.26% 659 $ 110.435K Nov 16, 2026
FLCV 1.23% 11,734 $ 1.717M Aug 31, 2026
RFFC 1.22% 2,703 $ 395.557K Aug 31, 2026
DIVD 1.21% 1,931 $ 330K Nov 18, 2026
BASV 1.12% 36,285 $ 4.584M Jun 30, 2026
MFSG 1.12% 28,973 $ 4.24M Aug 31, 2026
BRCE 1.09% 2,758 $ 403.606K Aug 31, 2026
SEIV 1.08% 125,751 $ 15.887M Jun 30, 2026
DFVX 1.04% 35,591 $ 5.978M Nov 12, 2026
CANC 1.02% 14,646 $ 2.143M Aug 31, 2026
CGBL 1.01% 481,299 $ 80.656M Nov 16, 2026
RFDA 0.99% 5,578 $ 816.285K Aug 31, 2026
MODL 0.94% 76,553 $ 9.672M Jun 30, 2026
FTLS 0.93% 143,553 $ 0.00 Nov 16, 2026
CGCV 0.91% 132,712 $ 22.24M Nov 16, 2026
JSTC 0.89% 15,654 $ 2.623M Nov 17, 2026
BALI 0.88% 80,687 $ 13.522M Nov 16, 2026
LSVD 0.87% 43,517 $ 5.666M Jul 31, 2026
ACLC 0.86% 19,142 $ 2.801M Aug 31, 2026
LCTU 0.85% 57,538 $ 9.642M Nov 16, 2026
BKDV 0.84% 118,425 $ 15.42M Jul 31, 2026
LSEQ 0.80% 753 $ 126.564K Nov 13, 2026
BLCR 0.78% 451,982 $ 75.743M Nov 16, 2026
TUG 0.78% 2,114 $ 267.083K Jun 30, 2026
GSPY 0.77% 31,650 $ 5.304M Nov 17, 2026
FLCC 0.76% 6,852 $ 1.003M Aug 31, 2026
FEAC 0.75% 1,545 $ 195.195K Jun 30, 2026
VFMF 0.73% 48,676 $ 7.123M Aug 31, 2026
CAPE 0.72% 13,578 $ 1.715M Jun 30, 2026
FYEE 0.72% 12,010 $ 1.564M Jul 31, 2026
AVSU 0.70% 20,142 $ 3.375M Nov 16, 2026
TUGN 0.69% 4,372 $ 552.358K Jun 30, 2026
FHEQ 0.68% 48,477 $ 6.312M Jul 31, 2026
FELV 0.64% 162,466 $ 20.526M Jun 30, 2026
DAK 0.63% 1,547 $ 260K Nov 18, 2026
GQQQ 0.63% 6,059 $ 1.03M Nov 18, 2026
GINX 0.63% 4,577 $ 669.798K Aug 31, 2026
FELC 0.62% 386,102 $ 48.78M Jun 30, 2026
FLSP 0.59% 44,237 $ 5.589M Jun 30, 2026
BDVL 0.58% 61,451 $ 10.298M Nov 16, 2026
FBCG 0.57% 301,197 $ 39.219M Jul 31, 2026
JGRO 0.56% 297,229 $ 50.606M Nov 17, 2026
OEI 0.55% 1,969 $ 256.383K Jul 31, 2026
SROI 0.55% 791 $ 102.996K Jul 31, 2026
DYNF 0.54% 1,340,178 $ 224.587M Nov 16, 2026
FFLC 0.53% 48,670 $ 6.337M Jul 31, 2026
UPSD 0.52% 4,670 $ 608.081K Jul 31, 2026
MSLC 0.52% 143,783 $ 21.041M Aug 31, 2026
INCE 0.51% 5,136 $ 648.882K Jun 30, 2026
AVUS 0.51% 438,256 $ 73.443M Nov 16, 2026
INFO 0.50% 26,510 $ 4.456M Nov 13, 2026
INRO 0.49% 17,112 $ 2.868M Nov 16, 2026
RCGE 0.49% 2,850 $ 490K Nov 18, 2026
PAPI 0.48% 15,349 $ 1.939M Jun 30, 2026
XMAG 0.48% 6,121 $ 1.028M Nov 13, 2026
DFSU 0.47% 67,258 $ 11.296M Nov 12, 2026
SFTY 0.46% 25,035 $ 3.664M Aug 31, 2026
STOX 0.46% 7,084 $ 1.037M Aug 31, 2026
BDYN 0.45% 81,319 $ 13.627M Nov 16, 2026
AVLC 0.44% 41,116 $ 6.89M Nov 16, 2026
VSLU 0.43% 18,636 $ 2.354M Jun 30, 2026
HUSV 0.42% 1,422 $ 238.299K Nov 16, 2026